Itolizumab regulates activating and inhibitory signals on effector cells, improving their cytotoxicity against CD318+ tumor cell lines
IntroductionThe CD6‐CD318 axis has emerged as a potential target for immuno‐oncology. Recent work has shown that blocking the CD6‐CD318 interaction with a murine anti‐human CD6 antibody increases lymphocyte cytotoxicity. However, several studies have d…